Improving biologics
through antibody innovation

Expanding the horizons of targeting and therapeutic possibilities

Our mission

Our aim is to expand the horizon of targeting and therapeutic possibilities of antibodies and Fc fusion proteins to improve medical outcomes

The problem

The nature of native Fc fragments limits  protein fusion possibilities

Native Fc fragments are homodimeric, consisting of two identical chains

Protein fusion to the native Fc fragment results in bivalency & monospecificity

These features limit the possibilities by which protein fusions can be displayed

The solution

AGGAbody enables tailored specificity  and valency of Fc protein fusions

Heterodimeric Fc fusion technology

The AGGAbody platform, co-developed with researchers at BOKU, Vienna, enables the isolation of heterodimeric Fc fusion proteins through a simple purification strategy

Mono- and multi-valency with defined specificity

Antigen binding scaffolds, bioactive protein and peptide fusion as combinations and orientations

One-pot expression of heterodimer and homodimer controls

AGGAbody’s one-pot expression and simple purification strategy delivers not only the heterodimeric Fc fusion but also the corresponding homodimeric fusions, which are invaluable as controls

Retention of wild-type properties

The minimal engineering involved has resulted in a heterodimeric Fc fragment with wild-type like properties

Available for outlicensing

Contact us to learn more about AGGA Biotech

AGGAbody

AGGAbody technology allows
for variable fusion proteins

AGGA’s patented technology can overcome the traditional challenges posed in realising the benefits of combined hetero- and homo-dimeric fusions

Team

Phil Jones, PhD

Cert Bus Admin - Founder

Phil is the co-inventor of the AGGAbody technology. Phil has over 20 years of experience in antibody drug discovery and protein engineering. Phil started his antibody discovery journey in the laboratory of Greg Winter and continued his passion for R&D at Domantis and at F-star as Director of Technology. More recently he has held client facing roles as a Team Leader at John McCafferty’s company, Iontas, and as VP of Discovery at RxBiologics.

Partnership & Consultancy

AGGA Biotech is pursing further innovations that will enhance antibodies and Fc fusion formats

We are always interested in and looking for new partnerships to help advance the platform

In addition to growing AGGA’s platform, Phil is also available for biotech R&D consultancy specialising in management, early stage discovery, protein engineering, display technologies and antibody therapeutics

Contact us